IVI Barcelona S.L.
- Address
- Calle Mallorca 45, 08029 Barcelona, Spain
Female Urogenital Health and Reproductive Medicine
At IVI Barcelona S.L., clinical research in Gynecology focuses on female infertility and care for women with an indication for IVF/ICSI. The studies explore ways to improve reproductive outcomes and better understand how the female reproductive system responds to treatment.
- Research on reproductive and urinary physiological phenomena linked to ovarian and uterine function
- Studies in female urogenital diseases related to infertility and assisted reproduction
- Evaluation of approaches aimed at supporting fertility treatment effectiveness and patient outcomes
The trial portfolio includes work on hormonal support after ovarian stimulation, methods to improve results in women with low ovarian reserve, and assessment of agents that may influence uterine activity during fertility care.
Assisted Reproduction and Ovarian Function
This research area centers on understanding and improving ovarian and uterine responses in fertility treatment. The trials are designed to test new or supportive strategies that may help optimize egg production, reproductive physiology, and overall treatment success.
- Testing a hormonal approach to see whether it affects ovarian size after stimulation
- Studying whether platelet-rich plasma and growth factor-based treatment may improve IVF outcomes in patients with reduced ovarian reserve
- Assessing the impact of a treatment on uterine contractility to better understand reproductive function
The site’s clinical work reflects a focused effort to refine fertility-related care through interventions that may support egg retrieval, reproductive performance, and the biological conditions needed for successful conception.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Ivi Alicante S.L.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in IVI Barcelona S.L.
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effects of Nolasiban Dosing Regimens on Uterine Contractility and Endocrine Parameters in Women Undergoing IVF/ICSI | ReproNovo ApS | Phase II | Recruiting | Jun 2026 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Letrozole | 1 | Unknown | 2023-12-04 | 2023-12-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.